313 related articles for article (PubMed ID: 21697032)
1. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis.
De Simone C; D'Agostino M; Capizzi R; Capponi A; Venier A; Caldarola G
Eur J Dermatol; 2011; 21(4):568-72. PubMed ID: 21697032
[TBL] [Abstract][Full Text] [Related]
2. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
Kircik L; Bagel J; Korman N; Menter A; Elmets CA; Koo J; Yang YC; Chiou CF; Dann F; Stevens SR;
J Drugs Dermatol; 2008 Mar; 7(3):245-53. PubMed ID: 18380206
[TBL] [Abstract][Full Text] [Related]
3. A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients.
Park KK; Wu JJ; Koo J
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):899-906. PubMed ID: 22702846
[TBL] [Abstract][Full Text] [Related]
4. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks.
Gambichler T; Tigges C; Scola N; Weber J; Skrygan M; Bechara FG; Altmeyer P; Kreuter A
Br J Dermatol; 2011 Jun; 164(6):1383-6. PubMed ID: 21466532
[TBL] [Abstract][Full Text] [Related]
5. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis.
Calzavara-Pinton PG; Sala R; Arisi M; Rossi MT; Venturini M; Ortel B
Br J Dermatol; 2013 Jul; 169(1):130-6. PubMed ID: 23834117
[TBL] [Abstract][Full Text] [Related]
6. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept.
Wolf P; Hofer A; Legat FJ; Bretterklieber A; Weger W; Salmhofer W; Kerl H
Br J Dermatol; 2009 Jan; 160(1):186-9. PubMed ID: 19067710
[TBL] [Abstract][Full Text] [Related]
7. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Gisondi P; Del Giglio M; Cotena C; Girolomoni G
Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
[TBL] [Abstract][Full Text] [Related]
8. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
11. Etanercept treatment for children and adolescents with plaque psoriasis.
Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
[TBL] [Abstract][Full Text] [Related]
12. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
Cassano N; Loconsole F; Galluccio A; Miracapillo A; Pezza M; Vena GA
Int J Immunopathol Pharmacol; 2006; 19(1):225-9. PubMed ID: 16569361
[TBL] [Abstract][Full Text] [Related]
13. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
14. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
15. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of etanercept and phototherapy-resistant psoriasis using the excimer laser.
Park KK; Swan J; Koo J
Dermatol Online J; 2012 Mar; 18(3):2. PubMed ID: 22483513
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
18. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study.
Mazzotta A; Esposito M; Schipani C; Chimenti S
J Dermatolog Treat; 2009; 20(6):354-8. PubMed ID: 19954392
[TBL] [Abstract][Full Text] [Related]
19. Our experience with etanercept in the treatment of psoriasis.
Kokelj F; Miertusova Tothova S; Patamia M; Trevisan G
Acta Dermatovenerol Croat; 2006; 14(4):241-5. PubMed ID: 17311738
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
